71 filings
Page 4 of 4
6-K
5byp4 ud9
13 Apr 21
Report of Foreign Private Issuer
6:14am
6-K
vhwhc k4s
5 Mar 21
Notice of ANNUAL General Meeting of shareholders
4:06pm
6-K
k5w5bk0q8y3hjm 0cc
17 Feb 21
Top-line Data Anticipated by Year End 2021
6:45am
6-K
3sj1iz1hi4jzh aha
10 Feb 21
PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
4:02pm
6-K
gq3trhmtj
22 Dec 20
PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program
8:42am
6-K
d5451u
16 Dec 20
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
9:07am
6-K
t7vgpz7c noo
24 Nov 20
PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX100for the Prevention of Surgical Site Infections in Colorectal Surgery
4:02pm
6-K
kbb7t
12 Nov 20
PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
6:05am
6-K
o4bdhsv
19 Aug 20
PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results
8:37am
6-K
yz5sw
3 Aug 20
PolyPid granted Fast Track Designation from FDA for D-PLEX100
4:00pm
6-K
m10m8 h0wua3if3u
1 Jul 20
PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:11pm